- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01867190
Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia (CLI)
February 20, 2019 updated by: Lifecells, LLC.
An Open-label Single Arm Phase 2 Proof of Concept Study to Assess the Efficacy and Safety of ASCT01 in Patients With Critical Limb Ischemia
This study will assess the safety and efficacy of intra-arterial infusion and intramuscular injection of an autologous, bone marrow-derived stem cell preparation (ASCT01) in patients with critical limb ischemia who have exhausted all medical and surgical therapeutic options.
The safety and tolerability will be evaluated by regular monitoring of the general physical condition, vital signs, and the occurrence of AE and SAE, respectively.
Furthermore, the standard biochemical and blood variables (red and white blood cell counts, Hb, Ht, platelets, sodium, potassium, chloride, calcium, phosphor, ASAT, ALAT, bilirubin, total protein, albumin, AP, cholesterol (LDL,HDL), triglycerides, urea and creatinine, immunoglobulins, HBA1c, C-peptide) will be checked before the treatment as well as 30 and 90 days after the treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Efficacy will be determined by number of collateral arteries as assessed magnetic resonance angiography at baseline and again at 3 months, rate of major amputation (above the ankle) of the affected limb within 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure.Efficacy endpoint is at 3 months.
Clinical endpoints and safety will be measured through 12 months.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
North Kansas City, Missouri, United States, 64116
- Kansas City Vascular Foundation (KCV)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and Female patients in the age group of 18-80yrs.
- Established CLI (confirmed by Rutherford 4 to 5) with angiographic evidence of significant infra-inguinal arterial occlusive disease
- Ankle Brachial Pressure Index (ABI) ≤ 0.6 or the absolute ankle blood pressure < 60 mm Hg or TcPO2<20 mmHg without tissue loss or TcPO2<40 mmHg if there is tissue loss or alternatively toe Brachial Pressure Index (TBI) less 0.5 or the absolute toe blood pressure less than 50 mm Hg
- No surgical or interventional option for revascularization and no response to best standard care delivered as confirmed by a vascular surgeon and/or physician.
- No immediate life-threatening complication from CLI which would demand immediate amputation.
- Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits.
- On optimal medical therapy
- If diabetic, HgbA1c <10%
Exclusion Criteria:
- Acute life threatening complication of limb ischemia with the need for immediate limb amputation to avoid death or clinical deterioration
- Patients with confirmed Rutherford 6 condition with extensive tissue damage
- Patients with documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 6 months.
- Patients with a history of severe alcohol or drug abuse within 3 months of screening.
- Known bone marrow diseases which preclude transplantation.
- End-stage renal failure on regular dialysis treatment. Creatinine ≥2.0 mg/dl
- Patients already enrolled in another investigational drug trial or completed within 1month.
- Pregnancy.
- Patients tested positive for HIV screen1or2, Hepatitis C antibody Hepatitis B surface-antigen, HepatitisBcore Antibody, Syphilis screen
- Myocardial infarction / CVA / TIA within the past three months prior to enrollment
- Revascularization procedure in target limb within 6 weeks prior to enrollment
- Laboratory values as show below*
- Currently taking immunosuppressive agents
- If diabetic, diagnosis of proliferative retinopathy
- Patients with infected ulcers or systemic infections *Laboratory Values: Hemoglobin <10 g/dL Platelet count <100,000/microL ALT >60 U/L AST >60 U/L Bilirubin >1.0 mg/dL INR >1.3 unless on Coumadin and at Investigator discretion APTT >40 second unless on Lovenox or Heparin and at Investigator's discretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: ASCT01
ASCT01 (Autologous Stem Cell Transplantation)
|
Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the efficacy and safety of intra-arterial infusion and intramuscular injection of ASCT01 on the combined primary endpoint of major amputation (above the ankle) or persisting critical limb ischemia (no clinical or perfusion improvement).
Time Frame: primary outcome measured at 3 months
|
The primary outcome variable is "treatment failure" defined as major amputation (above the ankle) of the affected limb within 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure.
|
primary outcome measured at 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Paul T Sudhakar, MS, Pharm, Lifecells, LLC.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
May 29, 2013
First Submitted That Met QC Criteria
May 31, 2013
First Posted (Estimate)
June 3, 2013
Study Record Updates
Last Update Posted (Actual)
February 22, 2019
Last Update Submitted That Met QC Criteria
February 20, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IND 15069
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.Not yet recruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening Ischemia
-
Lithuanian University of Health SciencesRecruiting
-
Taiwan Bio Therapeutics Co., Ltd.Completed
-
Tissue GenesisU.S. Army Medical Research and Development CommandActive, not recruitingCritical Limb IschemiaUnited States
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRIActive, not recruiting
-
ReFlow Medical, Inc.Massachusetts General Hospital; Syntropic CorelabCompletedCritical Limb IschemiaDominican Republic
-
Reven Pharmaceuticals, Inc.ICON plc; ERT: Clinical Trial Technology SolutionsCompletedCritical Limb IschemiaUnited States
-
Assiut UniversityUnknown
-
Ottawa Hospital Research InstituteThe Ottawa HospitalCompletedCritical Limb IschemiaCanada
-
HemostemixSuspendedCritical Limb IschemiaCanada
Clinical Trials on ASCT01 (Autologous Stem Cell Transplantation)
-
Northwestern UniversityTerminated
-
Chaitanya Hospital, PuneUnknown
-
Peking UniversityUnknown
-
Northwestern UniversityTerminated
-
Uppsala UniversityKarolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaboratorsCompletedImpact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden (AutoCOVID-19)Covid19 | Hematologic Neoplasms | Stem Cell Transplant Complications | Myeloma Multiple | Malignant LymphomaSweden
-
Federal Research Clinical Center of Federal Medical...Novagenesis Foundation; Ophiuchus Technologies AGUnknownSpinal Cord InjuryRussian Federation
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of TehranCompletedCirrhosisIran, Islamic Republic of
-
Chaitanya Hospital, PuneUnknown